ANNE TSAO to Mutation
This is a "connection" page, showing publications ANNE TSAO has written about Mutation.
Connection Strength
0.500
-
The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21.
Score: 0.105
-
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9.
Score: 0.064
-
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.
Score: 0.047
-
Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
Score: 0.038
-
The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018 02 12; 33(2):244-258.e10.
Score: 0.037
-
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
Score: 0.026
-
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20.
Score: 0.026
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.024
-
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.
Score: 0.018
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
Score: 0.015
-
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer. Future Oncol. 2024; 20(16):1047-1055.
Score: 0.014
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506.
Score: 0.014
-
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 07 20; 41(21):3700-3711.
Score: 0.013
-
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.
Score: 0.012
-
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small?cell lung cancer: phase II PHAROS study design. Future Oncol. 2022 Mar; 18(7):781-791.
Score: 0.012
-
Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5.
Score: 0.012
-
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.
Score: 0.011
-
Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 08; 11(8):1246-1262.
Score: 0.008
-
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20; 26(9):1472-8.
Score: 0.005